• Users Online: 109
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 16-22

Bromodomain and extra-terminal (BET) domain protein inhibitors for solid tumor cancers

Sarah Cannon Research Institute at HealthONE, Denver, CO, USA

Correspondence Address:
Martin V Nguyen
Sarah Cannon Research Institute at HealthONE, Denver, CO
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/JIPO.JIPO_2_20

Get Permissions

The bromodomain and extraterminal (BET) domain protein family is involved in the process of transcription of genetic information. The BET protein family includes BRD2, BRD3, BRD4, and bromodomain testis-specific protein. BET protein alterations are associated with some solid tumor cancers, including nuclear protein in testis midline carcinoma. BET protein has a role in carcinogenesis and in the regulation of the cell cycle. A number of BET inhibitors have entered clinical trials. This review discusses the results of BET inhibitor clinical trials in solid tumor cancers.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded56    
    Comments [Add]    

Recommend this journal